RxSightRXST -2.85%68 EBIT per Share is $-1.13 as of Mar. 2026. GuruFocus rates RXST with a GF Score™ of 68/100 and a GF Value™ of $35.80 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 688 Medical Devices & Instruments companies, RxSight ranks better than 64.83% on this metric.
RxSight's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.38.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.13.
During the past 3 years, the average EBIT per Share Growth Rate was 19.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 18.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for RxSight's EBIT per Share or its related term are showing as below:
RXST'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 2.6 Med: 13.8 Max: 37.5
Current: 19.8
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of RxSight was 37.50% per year. The lowest was 2.60% per year. And the median was 13.80% per year.
RXST's 3-Year EBIT Growth Rate is ranked better than 64.83% of 688
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs RXST: 19.80
RxSight's EBIT for the
three
months ended in Mar. 2026 was $-15.9 Mil.
RxSight (NAS:RXST) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
RxSight EBIT per Share Related Terms
RxSight EBIT per Share Historical Data
* Premium members only.
The historical data trend for RxSight's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RxSight (RXST) has a EBIT per Share of $-1.13 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on RxSight and its competitors. According to the industry distribution chart, RxSight ranks #242 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 35.2%.
Is RxSight's EBIT per Share too high?
RxSight's current EBIT per Share is $-1.13. Based on the distribution chart, RxSight ranks #242 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, RxSight has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RxSight's EBIT per Share compare to LUCD and QTRX?
According to the Medical Devices & Instruments industry distribution chart, RxSight ranks #242 out of 688 companies for EBIT per Share. This puts RxSight in the upper half of its industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on RxSight and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RxSight's current EBIT per Share is $-1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RxSight stock overvalued right now?
Based on GuruFocus' analysis, RxSight (RXST) is currently considered Possible Value Trap. The stock's GF Value™ is $35.80, compared to a current price of $4.95 — trading 86.2% below its estimated fair value. The current EBIT per Share is $-1.13. RxSight's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For RxSight (RXST), the current EBIT per Share is $-1.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RxSight (RXST) Overvalued in 2026?
Based on GuruFocus' analysis, RxSight stock appears to be undervalued.
The current stock price of $4.95 is trading 86.2% below its estimated GF Value™ of $35.80.
GuruFocus considers RxSight to be Possible Value Trap.
Key valuation signals for RXST:
EBIT per Share: $-1.13
GF Value™: $35.80 vs. price of $4.95 (86.2% below fair value)
No single metric tells the full story. See the RXST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
68GF Score
Get the complete analysis for RXST
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RXST has been successfully added to your 
